Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Sci Rep ; 6: 18517, 2016 Jan 05.
Article in English | MEDLINE | ID: mdl-26729235

ABSTRACT

Invasive lobular carcinoma (ILC) is the second most frequently occurring histological breast cancer subtype after invasive ductal carcinoma (IDC), accounting for around 10% of all breast cancers. The molecular processes that drive the development of ILC are still largely unknown. We have performed a comprehensive genomic, transcriptomic and proteomic analysis of a large ILC patient cohort and present here an integrated molecular portrait of ILC. Mutations in CDH1 and in the PI3K pathway are the most frequent molecular alterations in ILC. We identified two main subtypes of ILCs: (i) an immune related subtype with mRNA up-regulation of PD-L1, PD-1 and CTLA-4 and greater sensitivity to DNA-damaging agents in representative cell line models; (ii) a hormone related subtype, associated with Epithelial to Mesenchymal Transition (EMT), and gain of chromosomes 1q and 8q and loss of chromosome 11q. Using the somatic mutation rate and eIF4B protein level, we identified three groups with different clinical outcomes, including a group with extremely good prognosis. We provide a comprehensive overview of the molecular alterations driving ILC and have explored links with therapy response. This molecular characterization may help to tailor treatment of ILC through the application of specific targeted, chemo- and/or immune-therapies.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Carcinoma, Lobular/genetics , Carcinoma, Lobular/metabolism , Genomics , Proteome , Transcriptome , Biomarkers, Tumor , Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Carcinoma, Lobular/diagnosis , Cluster Analysis , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Epithelial-Mesenchymal Transition/genetics , Female , Gene Expression Profiling , Genomics/methods , Humans , Immunohistochemistry , Mutation Rate , Polymorphism, Single Nucleotide , Prognosis , Proteomics , Reproducibility of Results , Transcription Factors/genetics , Transcription Factors/metabolism
2.
Mol Oncol ; 9(8): 1528-38, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26004083

ABSTRACT

Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are mutant for the tumor suppressor, BRCA1. BRCA1 is required for homologous recombination-mediated DNA repair and deficiency results in genomic instability. BRCA1-mutated tumors have a specific pattern of genomic copy number aberrations that can be used to classify tumors as BRCA1-like or non-BRCA1-like. BRCA1 mutation, promoter methylation, BRCA1-like status and genome-wide expression data was determined for 112 TN breast cancer samples with long-term follow-up. Mutation status for 21 known DNA repair genes and PIK3CA was assessed. Gene expression and mutation frequency in BRCA1-like and non-BRCA1-like tumors were compared. Multivariate survival analysis was performed using the Cox proportional hazards model. BRCA1 germline mutation was identified in 10% of patients and 15% of tumors were BRCA1 promoter methylated. Fifty-five percent of tumors classified as BRCA1-like. The functions of genes significantly up-regulated in BRCA1-like tumors included cell cycle and DNA recombination and repair. TP53 was found to be frequently mutated in BRCA1-like (P < 0.05), while PIK3CA was frequently mutated in non-BRCA1-like tumors (P < 0.05). A significant association with worse prognosis was evident for patients with BRCA1-like tumors (adjusted HR = 3.32, 95% CI = 1.30-8.48, P = 0.01). TN tumors can be further divided into two major subgroups, BRCA1-like and non-BRCA1-like with different mutation and expression patterns and prognoses. Based on these molecular patterns, subgroups may be more sensitive to specific targeted agents such as PI3K or PARP inhibitors.


Subject(s)
Genes, BRCA1 , Molecular Targeted Therapy/trends , Transcriptome , Triple Negative Breast Neoplasms/classification , Triple Negative Breast Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Comparative Genomic Hybridization , DNA Methylation , DNA Mutational Analysis , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , High-Throughput Nucleotide Sequencing , Humans , Microarray Analysis , Middle Aged , Promoter Regions, Genetic , Triple Negative Breast Neoplasms/diagnosis , Triple Negative Breast Neoplasms/therapy
3.
Kidney Int ; 78(10): 1033-40, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20720522

ABSTRACT

The distinction between T-cell-mediated rejection (TCMR) and other causes of kidney transplant dysfunction such as tubular necrosis requires biopsy. Subclinical rejection (SCR), an established risk factor for chronic allograft dysfunction, can only be diagnosed by protocol biopsy. A specific non-invasive biomarker to monitor immunological graft status would facilitate diagnosis and treatment of common transplantation-related complications. To identify possible markers, we measured urinary mRNA levels of several cytolytic proteins by quantitative PCR. Our cohort of 70 renal transplant recipients had biopsy proven type I and type II TCMR, acute tubular necrosis, SCR, calcineurin inhibitor-toxicity, cytomegalovirus infection, and stable graft function with normal histology. Granzyme A (GzmA) mRNA was significantly higher in subclinical and acute cellular rejection compared to patients with stable grafts or those with tubular necrosis with 80% sensitivity and up to 100% specificity. Granzyme B and perforin mRNA levels could significantly discriminate acute rejection from stable or tubular necrosis, but were not significantly elevated during SCR. Importantly, only GzmA mRNA remained below detection limits from grafts that were stable and most with tubular necrosis. Hence, the presented data indicate that urinary GzmA mRNA levels may entail a diagnostic non-invasive biomarker to distinguish patients with subclinical and acute cellular rejection from those with tubular necrosis or stable grafts.


Subject(s)
Graft Rejection/diagnosis , Graft Rejection/urine , Granzymes/genetics , Kidney Transplantation , RNA, Messenger/urine , Adult , Aged , Biomarkers/urine , Biopsy , Cohort Studies , Diagnosis, Differential , Female , Humans , Kidney Tubules/pathology , Male , Middle Aged , Necrosis/diagnosis , Necrosis/urine , Perforin/genetics , Retrospective Studies , Sensitivity and Specificity
4.
Br J Haematol ; 145(3): 334-43, 2009 May.
Article in English | MEDLINE | ID: mdl-19245431

ABSTRACT

In human B cells, effective major histocompatibility complex (MHC) class II-antigen presentation depends not only on MHC class II, but also on the invariant chain (CD74 or Ii), HLA-DM (DM) and HLA-DO (DO), the chaperones regulating the antigen loading process of MHC class II molecules. We analysed immediate ex vivo expression of HLA-DR (DR), CD74, DM and DO in B cell chronic lymphocytic leukaemia (B-CLL). Real-time reverse transcription polymerase chain reaction demonstrated a highly significant upregulation of DRA, CD74, DMB, DOA and DOB mRNA in purified malignant cells compared to B cells from healthy donors. The increased mRNA levels were not translated into enhanced protein levels but could reflect aberrant transcriptional regulation. Indeed, upregulation of DRA, DMB, DOA and DOB mRNA correlated with enhanced expression of class II transactivator (CIITA). In-depth analysis of the various CIITA transcripts demonstrated a significant increased activity of the interferon-gamma-inducible promoter CIITA-PIV in B-CLL. Comparison of the aberrant mRNA levels with clinical outcome identified DOA mRNA as a prognostic indicator for survival. Multivariate analysis revealed that the prognostic value of DOA mRNA was independent of the mutational status of the IGHV genes. Thus, aberrant transcription of DOA forms a novel and additional prognostic indicator for survival in B-CLL.


Subject(s)
Gene Expression Regulation, Neoplastic , HLA-D Antigens/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Nuclear Proteins/genetics , RNA, Messenger/analysis , Trans-Activators/genetics , Transcription, Genetic , Aged , Antigen Presentation/genetics , Antigens, Differentiation, B-Lymphocyte/genetics , Case-Control Studies , Electrophoresis, Polyacrylamide Gel/methods , Female , HLA-DR Antigens/genetics , Histocompatibility Antigens Class II/genetics , Humans , Male , Middle Aged , Prognosis , Promoter Regions, Genetic , Proportional Hazards Models , Reverse Transcriptase Polymerase Chain Reaction/methods
6.
J Clin Pathol ; 60(2): 167-72, 2007 Feb.
Article in English | MEDLINE | ID: mdl-16837630

ABSTRACT

BACKGROUND: Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is highly variable and poorly predictable. Microarray studies showed that patients with DLBCL with a germinal centre B cell-like (GCB) phenotype have a better prognosis than those with an activated B cell-like (ABC) phenotype. The BMI1 proto-oncogene was identified as one of the genes present in the signature of the ABC type of DLBCL, associated with a poor prognosis. OBJECTIVES: (1) To investigate, in primary nodal DLBCL, the expression of BMI1 and its association with clinical outcome and DLBCL signature; (2) to look for an association between BMI1 expression and the expression of its putative downstream targets p14ARF and p16INK4a. RESULTS: BMI1 expression was found to be associated with poor clinical outcome, but not clearly with an ABC-like phenotype of DLBCL. Expression of BMI1 was frequently, but not always, related to low levels of expression of p14ARF and p16INK4a. CONCLUSION: Expression of BMI1 is associated with an unfavourable clinical outcome of primary nodal DLBCL.


Subject(s)
Biomarkers, Tumor/metabolism , Lymphoma, B-Cell/metabolism , Lymphoma, Large B-Cell, Diffuse/metabolism , Nuclear Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Repressor Proteins/metabolism , Adult , Aged , Aged, 80 and over , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Female , Humans , Immunoenzyme Techniques , Lymphocyte Activation , Male , Middle Aged , Neoplasm Proteins/metabolism , Nuclear Proteins/genetics , Polycomb Repressive Complex 1 , Prognosis , Proto-Oncogene Mas , Proto-Oncogene Proteins/genetics , Repressor Proteins/genetics , Survival Analysis , Tumor Suppressor Protein p14ARF/metabolism
7.
Br J Haematol ; 134(3): 283-93, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16848771

ABSTRACT

Resistance to chemotherapy in therapy-refractory diffuse large B-cell lymphomas (DLBCL) is related to inhibition of the intrinsic apoptosis pathway. Human soluble tumour necrosis factor (TNF)-related apoptosis-inducing ligand (hsTRAIL/Apo2L) induces apoptosis via the alternative, death-receptor mediated apoptosis pathway and might be an effective alternative form of therapy for these lymphomas. This study investigated whether hsTRAIL/Apo2L could actually induce apoptosis in isolated lymphoma cells of DLBCL biopsies of patients with chemotherapy-refractory DLBCL. Twelve out of a total of 22 DLBCL samples were sensitive to hsTRAIL/Apo2L. These sensitive lymphomas included seven clinically chemotherapy-refractory lymphomas. Furthermore, hsTRAIL/Apo2L induced apoptosis in DLBCL cells and in B-cell lines that showed high expression levels of inhibitors of the intrinsic apoptosis pathway: Bcl-2 and/or X-linked inhibitor of apoptosis (XIAP). hsTRAIL/Apo2L-sensitive lymphoma cells showed expression of the TRAIL receptors R1 and/or R2 and absence of R3 and R4. We conclude that hsTRAIL/Apo2L induced apoptosis in a subpopulation of chemotherapy-refractory nodal DLBCL and that disruption of the intrinsic apoptosis-mediated pathway and expression of Bcl-2 and XIAP did not confer resistance to hsTRAIL/Apo2L-induced apoptosis in DLBCL. Thus, based on our results, further exploration of hsTRAIL/Apo2L as an alternative treatment for patients with chemotherapy-refractory DLBCL should be considered.


Subject(s)
Apoptosis Regulatory Proteins/therapeutic use , Lymphoma, Large B-Cell, Diffuse/drug therapy , Membrane Glycoproteins/therapeutic use , Tumor Necrosis Factor-alpha/therapeutic use , Apoptosis/drug effects , Blotting, Western/methods , CASP8 and FADD-Like Apoptosis Regulating Protein , Caspase 3 , Caspases/metabolism , Cell Line, Tumor , Drug Resistance, Neoplasm , Fluorometry , Humans , Immunohistochemistry/methods , Intracellular Signaling Peptides and Proteins/analysis , Intracellular Signaling Peptides and Proteins/metabolism , Lymphatic Metastasis , Proto-Oncogene Proteins c-bcl-2/analysis , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptors, TNF-Related Apoptosis-Inducing Ligand , Receptors, Tumor Necrosis Factor/analysis , Receptors, Tumor Necrosis Factor/metabolism , TNF-Related Apoptosis-Inducing Ligand , X-Linked Inhibitor of Apoptosis Protein/analysis , X-Linked Inhibitor of Apoptosis Protein/metabolism
8.
Hematol Oncol ; 24(3): 97-104, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16715473

ABSTRACT

Diffuse large B-cell lymphomas (DLBCL) represent the most common type of adult malignant lymphoma in western countries and are treated with high dose combination chemotherapy. Although initially the majority of patients respond to this therapy, many do not achieve complete remission and others experience an early relapse. Several studies have shown that prediction of the clinical response to chemotherapy is possible before the start of chemotherapy treatment. Apparently, DLBCL are intrinsically either resistant or sensitive to chemotherapy-induced cell death. Differences in functional integrity of the apoptosis cascade are an important factor predicting outcome in DLBCL. In this review we discuss the possible mechanisms leading to intrinsic resistance to apoptosis and provide an explanation why strong differences in apoptosis sensitivity between DLBCL are observed. Subsequently we will focus on how differences in this intrinsic apoptosis resistance provide an explanation for the variable response to combination chemotherapy and how this can be used for further therapy tailoring.


Subject(s)
Apoptosis , Lymphoma, B-Cell/metabolism , Lymphoma, Large B-Cell, Diffuse/metabolism , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Apoptosis/drug effects , Humans , Lymphoma, B-Cell/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Recurrence , Remission Induction , Treatment Outcome
9.
Clin Cancer Res ; 11(17): 6400-7, 2005 Sep 01.
Article in English | MEDLINE | ID: mdl-16144945

ABSTRACT

PURPOSE: There have been reports of successful treatment of metastatic melanoma patients with active specific immunotherapy (ASI) using irradiated autologous tumor cell vaccination. It is still unknown why some patients respond and others do not. Tumor cells can evade the immune system, for example through interference with antigen presentation by down-regulation of MHC molecules or expressing proteins interfering with cytotoxic lymphocyte-induced apoptosis like the granzyme B antagonist protease inhibitor 9 (PI-9). EXPERIMENTAL DESIGN: PI-9 expression was detected in melanoma cell lines. To investigated if PI-9 is important in the response to ASI, paraffin-embedded tissues from stage III or IV melanoma patients were stained. RESULTS: PI-9 is expressed in melanoma cells and expression in metastasized melanoma cells is, in this group of patients, an adverse prognostic marker with regard to overall and disease-free survival. Moreover, loss of MHC-1 expression frequently occurs during tumor progression but is not associated with poor clinical outcome. Interestingly, melanoma patients with a favorable clinical outcome after ASI therapy usually have high percentages of activated (granzyme B-positive) tumor-infiltrating lymphocytes at time of first diagnosis and low percentages of activated lymphocytes at time of recurrent tumor. CONCLUSIONS: Expression of PI-9 in metastatic melanoma cells is associated with unfavorable clinical outcome whereas MHC-1 down-regulation is not. Although it cannot be proven that PI-9 expression is directly responsible for failure of immunotherapy, these data suggest that expression of PI-9 could be an important immune escape mechanism and that modulation of this inhibitor may enhance the efficacy of immunotherapy.


Subject(s)
Apoptosis , Cancer Vaccines/therapeutic use , Lymphocytes, Tumor-Infiltrating/pathology , Melanoma/immunology , Serpins/metabolism , Skin Neoplasms/immunology , Adult , Aged , Blotting, Western , Disease-Free Survival , Female , Genes, MHC Class I/physiology , Granzymes , Humans , Immunoenzyme Techniques , Immunotherapy , Lymphocyte Activation , Male , Melanoma/secondary , Melanoma/therapy , Middle Aged , Neoplasm Staging , Serine Endopeptidases/chemistry , Skin Neoplasms/secondary , Skin Neoplasms/therapy , Survival Rate , Treatment Outcome , Tumor Cells, Cultured
10.
J Pathol ; 206(3): 328-36, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15887291

ABSTRACT

Loss of both HLA class I and class II expression in B cell lymphomas is a mechanism of escape from a cytotoxic T lymphocyte (CTL) immune response and will therefore give a strong selective survival advantage in tumours expressing strong immunogenic antigens. We investigated loss of HLA expression using specific antibodies on tissue sections from 254 B cell lymphomas originating from nodal and different extranodal sites in relation to numbers of tumour-infiltrating T cells. Complete loss of HLA class I and II was observed in a minority of the nodal, stomach, and skin lymphomas but in the majority of the lymphomas originating from the testis and the CNS. Interestingly, relatively high percentages of activated CTLs were detected in both primary testicular and CNS lymphomas compared to lymphomas at other sites, with highest percentages in the testis (p < 0.0001). We conclude that loss of both HLA class I and II expression occurs very frequently in lymphomas originating from the testis and the CNS as compared to nodal and some other extranodal sites. The presence of high percentages of activated CTLs in the testicular and CNS lymphomas suggests that loss of HLA expression provides a strong growth advantage for lymphoma cells in these immune-privileged sites.


Subject(s)
Brain Neoplasms/genetics , HLA Antigens/genetics , Lymphoma, B-Cell/genetics , Lymphoma, Large B-Cell, Diffuse/genetics , T-Lymphocytes, Cytotoxic/immunology , Testicular Neoplasms/genetics , Brain Neoplasms/immunology , CD3 Complex/genetics , CD3 Complex/immunology , CD4 Antigens/analysis , CD4 Antigens/genetics , CD8 Antigens/analysis , CD8 Antigens/genetics , Gene Expression Regulation, Neoplastic/genetics , Gene Expression Regulation, Neoplastic/immunology , HLA Antigens/immunology , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology , Histocompatibility Antigens Class II/genetics , Histocompatibility Antigens Class II/immunology , Humans , Lymphocyte Count/methods , Lymphocytes, Tumor-Infiltrating/immunology , Lymphoma, B-Cell/immunology , Lymphoma, Large B-Cell, Diffuse/immunology , Male , Phenotype , Skin Neoplasms/genetics , Skin Neoplasms/immunology , Stomach Neoplasms/genetics , Stomach Neoplasms/immunology , T-Lymphocyte Subsets/immunology , Testicular Neoplasms/immunology
11.
Cell Cycle ; 4(4): 526-8, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15876872

ABSTRACT

Clinical response to chemotherapy in patients with diffuse large B-cell lymphomas is poorly predictable. We demonstrated that an expression profile consistent with inhibition of the stress-induced, caspase 9 mediated apoptosis pathway predicts poor clinical response to chemotherapy, whereas an expression profile consistent with inhibition of only the death-receptor induced, caspase 8 mediated pathway was associated with an excellent response to chemotherapy and favorable outcome. Furthermore, functional analysis of apoptosis sensitivity showed that lymphomas with a caspase 9 inhibition profile were indeed relatively resistant to Etoposide induced apoptosis. Determining the functional status of both apoptosis signaling pathways may accurately identify patients at high risk for fatal outcome and may have implications for alternative therapies triggering the death receptor mediated apoptosis pathway.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis , Caspase Inhibitors , Drug Resistance, Neoplasm , Lymphoma, B-Cell/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Animals , Caspase 8 , Caspase 9 , Enzyme Inhibitors , Etoposide/pharmacology , Humans , Lymphoma, B-Cell/pathology , Lymphoma, Large B-Cell, Diffuse/pathology , Models, Biological , Risk , Signal Transduction , Treatment Outcome
12.
Blood ; 105(7): 2916-23, 2005 Apr 01.
Article in English | MEDLINE | ID: mdl-15576477

ABSTRACT

We used biopsy specimens of primary nodal diffuse large B-cell lymphoma (DLBCL) to investigate whether the inhibition of caspase 8 and/or 9 apoptosis signaling pathways predicts clinical outcome. Expression levels of cellular FLICE inhibitory protein (c-Flip) and numbers of active caspase 3-positive lymphoma cells were used to determine the status of the caspase 8-mediated pathway. Expression levels of Bcl-2 and X-linked inhibitor of apoptosis (XIAP) were used to determine the status of the caspase 9-mediated pathway. Expression of c-Flip, XIAP, Bcl-2, and caspase 3 activity all provided prognostic information. According to these immunohistochemical parameters, inhibition of either or both caspase signaling pathways was detected in all patients. Three groups of patients were identified, one with a caspase 8 inhibition profile, one with caspase 8 and 9 inhibition profiles, and one with a caspase 9 inhibition profile. Caspase 9 inhibition was strongly associated with poor response to chemotherapy and usually with fatal outcome, whereas caspase 8 inhibition was associated with excellent clinical outcome. Thus, our data strongly suggest that inhibition of the caspase 9-mediated pathway, but not the caspase 8-mediated pathway, is a major cause for therapy resistance in patients with nodal DLBCL.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Caspases/metabolism , Etoposide/administration & dosage , Lymphoma, B-Cell/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Signal Transduction/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Apoptosis/drug effects , Apoptosis/physiology , CASP8 and FADD-Like Apoptosis Regulating Protein , Caspase 3 , Caspase 8 , Caspase 9 , Female , Humans , Immunohistochemistry , Intracellular Signaling Peptides and Proteins/metabolism , Lymphoma, B-Cell/metabolism , Lymphoma, B-Cell/mortality , Lymphoma, B-Cell/pathology , Lymphoma, Large B-Cell, Diffuse/metabolism , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Poly(ADP-ribose) Polymerases/metabolism , Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Treatment Outcome , X-Linked Inhibitor of Apoptosis Protein
13.
Blood ; 99(1): 232-7, 2002 Jan 01.
Article in English | MEDLINE | ID: mdl-11756176

ABSTRACT

In tumor cells, the serine protease granzyme B is the primary mediator of apoptosis induced by cytotoxic T lymphocytes (CTLs)/natural killer (NK) cells. The human intracellular serpin proteinase inhibitor 9 (PI9) is the only known human protein able to inhibit the proteolytic activity of granzyme B. When present in the cytoplasm of T lymphocytes, PI9 is thought to protect CTLs against apoptosis induced by their own misdirected granzyme B. Based on the speculation that tumors may also express PI9 to escape CTL/NK cell surveillance, immunohistochemical studies on the expression of PI9 in various lymphomas were performed. Ninety-two cases of T-cell non-Hodgkin lymphoma (NHL), 75 cases of B-cell NHL, and 57 cases of Hodgkin lymphomas were stained with a PI9-specific monoclonal antibody. In T-cell NHL, highest PI9 expression was found in the extranodal T-cell NHL. In nearly 90% of enteropathy-type T-cell NHLs and 80% of NK/T-cell, nasal-type lymphomas, the majority of the tumor cells expressed PI9. In nodal T-anaplastic large cell lymphomas and peripheral T-cell lymphomas (not otherwise specified), PI9 expression occurred less frequently. In B-cell NHL, PI9 expression was associated with high-grade malignancy; 43% of diffuse large B-cell lymphomas showed PI9(+) tumor cells. Finally, PI9 expression was also found in 10% of Hodgkin lymphomas. This is the first report describing the expression of the granzyme B inhibitor PI9 in human neoplastic cells in vivo. Expression of this inhibitor is yet another mechanism used by tumor cells to escape their elimination by cytotoxic lymphocytes.


Subject(s)
Hodgkin Disease/immunology , Hodgkin Disease/metabolism , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/metabolism , Serine Endopeptidases/metabolism , Serpins/analysis , Antibodies, Monoclonal , Apoptosis , Granzymes , Histocytochemistry , Humans , Immunohistochemistry , Killer Cells, Natural/immunology , Lymphoma, B-Cell/immunology , Lymphoma, B-Cell/metabolism , Lymphoma, T-Cell/immunology , Lymphoma, T-Cell/metabolism , T-Lymphocytes, Cytotoxic/enzymology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...